Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...

Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...

Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...

Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

Biocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...

Eswara Reddy along with Animesh Kumar (Assistant Drugs Inspector), Biocon Biologics' Associate Vice President L Praveen Kumar, and Synergy ...

BBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...

Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...

With the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...

For the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 ...

Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...

Biocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...

As per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...

The Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...

The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...